However, the recent track record of European drug approvals, especially conditional approvals such as that of PTC's Translarna, may be described by a different set of adjectives that might range from 'incompetent' to 'pointless.'
written on 28.05.2014
STOCKWATCH: EU conditional approvals – what gives?
